Model-Informed Regulatory Science

PMTA evidence, modeled in an hour — not years.

Run virtual PK trials, excess-cancer-risk and population-health models right in your browser. Generate §1114.7-formatted supporting evidence and decide which formula to file — before you spend millions.

FDA NAMs 2026 ICH M15 MIDD NMPA 2020 CORESTA COMPUTE
The problem

Filing blind is a multi-million-dollar gamble

Before committing to clinical studies, you need credible early evidence to cut trial-and-error cost.

¥50M+

High cost of a wrong bet

Average full PMTA submission per single SKU — spent before you know if the formula clears.

2–5 yr

Decision cycles drag

From R&D kickoff to a marketing-granted order — too long to learn by filing.

No early quantitative data

Formula-screening stage lacks the numbers to rank candidates with confidence.

Three MIRS tools · one evidence chain

Computed evidence — not just drafted text

Each tool maps to a key FDA §1114.7 evidence element and runs entirely in your browser.

💊
PRODUCT 01 · §910(b) PK

InSilico-PK

Population-PK virtual clinical trial — Monte Carlo over a 500-subject cohort in the browser.

  • Cmax / Tmax / AUC + 5–95% prediction interval
  • CYP2A6 phenotype & weight covariates
  • VPC-style diagnostics, no fabricated data
Output: Cmax · Tmax · AUC₀–∞ · Benowitz 2009 PopPK
⚠️
PRODUCT 02 · §910(b) HPHC

ELCR Calculator

Excess lifetime cancer risk from HPHC concentrations, faithful to the FDA CTP 2024-06 memo.

  • Σ ELCR and % of 1R6F reference cigarette
  • OEHHA / EPA IRIS / IARC corrected IUR library
  • FDA 5-level concern auto-tiering
Output: Σ ELCR · % of 1R6F · vs MGO ENDS median
👥
PRODUCT 03 · §910(c)(4)

PHIA Model

Population health impact via a 5/6-state Markov model over a 50–75 year horizon.

  • PDA, LYG and adoption-ratio outputs
  • Dual tipping-point sensitivity (switch + youth)
  • Scenario A vs B comparison + Monte Carlo
Output: PDA · LYG · ΔCS% · CORESTA COMPUTE
Why regulators accept it

An FDA-encouraged scientific pathway

FDA's 2026 New Approach Methodologies draft lists in-silico models as a scientific alternative pathway. Our tools align with the mainstream frameworks — every report ships 14–21 traceable citations.

FDA NAMs (2026)ICH M15 MIDD FDA MIDD PilotNMPA 模型引导原则 (2020) NMPA PopPK (2020)CORESTA COMPUTE TF
How we differ

Quantitative evidence vs. AI writing assistants

Drafting tools rephrase your narrative. EBSH computes the numbers that narrative has to defend.

Capability AI writing assistants EBSH · MIRS
What it producesDrafted application textComputed PK / risk / PHIA values with CIs
Evidence typeNarrative only§910(b) & §910(c)(4) modeled evidence
ReproducibilityNot reproducibleSeeded Monte Carlo · version-pinned params
Data privacyUploaded to a cloud LLMStays in your browser — we never receive it
Best usedLate-stage draftingEarly go/no-go formula screening
Transparent · self-service

Four fixed prices. Buy online in 5 minutes.

No negotiation, no sales calls. Pick a plan, pay, and your account provisions automatically.

Pay your way: Stripe (Visa/Mastercard/Amex, USD) · Alipay · WeChat Pay · RMB corporate wire.
7-day full refund · on-demand 6% VAT e-invoice · cancel anytime from your dashboard.

See your formula's evidence today

Start the free in-browser trial, or book a 30-minute walkthrough of the three tools and the PMTA-ready report.

Runs in your browser — submission data never leaves it PMTA-ready PDF / HTML / JSON with full citations Account live within 5 minutes of payment

Start your free trial

No card required. We'll email demo credentials.
FAQ

About MIRS, the FDA & your data